Find Clinical Trials & Studies

Visit the Research & Education Institute

Roll-over Study Ribociclib (LEE011) Who Are on Ribociclib Treatment in Novartis

I'm Interested!

Please call
1-800-641-2422

A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study.

Sex: Female
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Breast

Study Purpose

The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in combination with other drugs and continuing to have clinical benefit in a Novartis-sponsored global study that has reached its primary objective(s).

Principal Investigator
Cynthia Owusu MD

Department/Division
Cancer (Breast)

UH IRB: Pro00063221
StudyID: NOVA1122
ClinicalTrials.gov: NCT05161195

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422